In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Yihan Wang, Chester A. Metcalf, Raji Sundaramoorthi, William C. Shakespeare, Joseph Snodgrass, Scott Wardwell, David Dalgarno, John Iuliucci, Tomi K. Sawyer, Michael Heinrich, Brian Druker, Michael W N Deininger

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Oncogenic mutations of the Kit receptor tyrosine kinase occur in several types of malignancy. Juxtamembrane domain mutations are common in gastrointestinal stromal tumors, whereas mutations in the kinase activation loop, most commonly D816V, are seen in systemic mastocytosis and acute myelogenous leukemia. Kit activation-loop mutants are insensitive to imatinib mesylate and have been largely resistant to targeted inhibition. We determined the sensitivities of both Kit mutant classes to the adenosine triphosphate (ATP)-based inhibitors AP23464 and AP23848. In cell lines expressing activation-loop mutants, low-nM concentrations of AP23464 inhibited phosphorylation of Kit and its downstream targets Akt and signal transducer and activator of transcription 3 (STAT3). This was associated with cell-cycle arrest and apoptosis. Wild-type Kit- and juxtamembrane-mutant-expressing cell lines required considerably higher concentrations for equivalent inhibition, suggesting a therapeutic window in which cells harboring D816V Kit could be eliminated without interfering with normal cellular function. Additionally, AP23464 did not disrupt normal hematopoietic progenitor-cell growth at concentrations that inhibited activation-loop mutants of Kit. In a murine model, AP23848 inhibited activation-loop mutant Kit phosphorylation and tumor growth. Thus, AP23464 and AP23848 potently and selectively target activation-loop mutants of Kit in vitro and in vivo and could have therapeutic potential against D816V-expressing malignancies.

Original languageEnglish (US)
Pages (from-to)227-234
Number of pages8
JournalBlood
Volume106
Issue number1
DOIs
StatePublished - Jul 1 2005
Externally publishedYes

Fingerprint

Phosphotransferases
Adenosine Triphosphate
Chemical activation
Mutation
Phosphorylation
Cells
Systemic Mastocytosis
Cell Line
STAT3 Transcription Factor
Neoplasms
Gastrointestinal Stromal Tumors
Tumors
Receptor Protein-Tyrosine Kinases
Growth
Hematopoietic Stem Cells
Cell Cycle Checkpoints
Acute Myeloid Leukemia
Cell growth
Apoptosis
AP23464

ASJC Scopus subject areas

  • Hematology

Cite this

Corbin, A. S., Demehri, S., Griswold, I. J., Wang, Y., Metcalf, C. A., Sundaramoorthi, R., ... Deininger, M. W. N. (2005). In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood, 106(1), 227-234. https://doi.org/10.1182/blood-2004-12-4771

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. / Corbin, Amie S.; Demehri, Shadmehr; Griswold, Ian J.; Wang, Yihan; Metcalf, Chester A.; Sundaramoorthi, Raji; Shakespeare, William C.; Snodgrass, Joseph; Wardwell, Scott; Dalgarno, David; Iuliucci, John; Sawyer, Tomi K.; Heinrich, Michael; Druker, Brian; Deininger, Michael W N.

In: Blood, Vol. 106, No. 1, 01.07.2005, p. 227-234.

Research output: Contribution to journalArticle

Corbin, AS, Demehri, S, Griswold, IJ, Wang, Y, Metcalf, CA, Sundaramoorthi, R, Shakespeare, WC, Snodgrass, J, Wardwell, S, Dalgarno, D, Iuliucci, J, Sawyer, TK, Heinrich, M, Druker, B & Deininger, MWN 2005, 'In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit', Blood, vol. 106, no. 1, pp. 227-234. https://doi.org/10.1182/blood-2004-12-4771
Corbin, Amie S. ; Demehri, Shadmehr ; Griswold, Ian J. ; Wang, Yihan ; Metcalf, Chester A. ; Sundaramoorthi, Raji ; Shakespeare, William C. ; Snodgrass, Joseph ; Wardwell, Scott ; Dalgarno, David ; Iuliucci, John ; Sawyer, Tomi K. ; Heinrich, Michael ; Druker, Brian ; Deininger, Michael W N. / In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. In: Blood. 2005 ; Vol. 106, No. 1. pp. 227-234.
@article{4578878ee37e4757a4eb09b13888d1b8,
title = "In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit",
abstract = "Oncogenic mutations of the Kit receptor tyrosine kinase occur in several types of malignancy. Juxtamembrane domain mutations are common in gastrointestinal stromal tumors, whereas mutations in the kinase activation loop, most commonly D816V, are seen in systemic mastocytosis and acute myelogenous leukemia. Kit activation-loop mutants are insensitive to imatinib mesylate and have been largely resistant to targeted inhibition. We determined the sensitivities of both Kit mutant classes to the adenosine triphosphate (ATP)-based inhibitors AP23464 and AP23848. In cell lines expressing activation-loop mutants, low-nM concentrations of AP23464 inhibited phosphorylation of Kit and its downstream targets Akt and signal transducer and activator of transcription 3 (STAT3). This was associated with cell-cycle arrest and apoptosis. Wild-type Kit- and juxtamembrane-mutant-expressing cell lines required considerably higher concentrations for equivalent inhibition, suggesting a therapeutic window in which cells harboring D816V Kit could be eliminated without interfering with normal cellular function. Additionally, AP23464 did not disrupt normal hematopoietic progenitor-cell growth at concentrations that inhibited activation-loop mutants of Kit. In a murine model, AP23848 inhibited activation-loop mutant Kit phosphorylation and tumor growth. Thus, AP23464 and AP23848 potently and selectively target activation-loop mutants of Kit in vitro and in vivo and could have therapeutic potential against D816V-expressing malignancies.",
author = "Corbin, {Amie S.} and Shadmehr Demehri and Griswold, {Ian J.} and Yihan Wang and Metcalf, {Chester A.} and Raji Sundaramoorthi and Shakespeare, {William C.} and Joseph Snodgrass and Scott Wardwell and David Dalgarno and John Iuliucci and Sawyer, {Tomi K.} and Michael Heinrich and Brian Druker and Deininger, {Michael W N}",
year = "2005",
month = "7",
day = "1",
doi = "10.1182/blood-2004-12-4771",
language = "English (US)",
volume = "106",
pages = "227--234",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

AU - Corbin, Amie S.

AU - Demehri, Shadmehr

AU - Griswold, Ian J.

AU - Wang, Yihan

AU - Metcalf, Chester A.

AU - Sundaramoorthi, Raji

AU - Shakespeare, William C.

AU - Snodgrass, Joseph

AU - Wardwell, Scott

AU - Dalgarno, David

AU - Iuliucci, John

AU - Sawyer, Tomi K.

AU - Heinrich, Michael

AU - Druker, Brian

AU - Deininger, Michael W N

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Oncogenic mutations of the Kit receptor tyrosine kinase occur in several types of malignancy. Juxtamembrane domain mutations are common in gastrointestinal stromal tumors, whereas mutations in the kinase activation loop, most commonly D816V, are seen in systemic mastocytosis and acute myelogenous leukemia. Kit activation-loop mutants are insensitive to imatinib mesylate and have been largely resistant to targeted inhibition. We determined the sensitivities of both Kit mutant classes to the adenosine triphosphate (ATP)-based inhibitors AP23464 and AP23848. In cell lines expressing activation-loop mutants, low-nM concentrations of AP23464 inhibited phosphorylation of Kit and its downstream targets Akt and signal transducer and activator of transcription 3 (STAT3). This was associated with cell-cycle arrest and apoptosis. Wild-type Kit- and juxtamembrane-mutant-expressing cell lines required considerably higher concentrations for equivalent inhibition, suggesting a therapeutic window in which cells harboring D816V Kit could be eliminated without interfering with normal cellular function. Additionally, AP23464 did not disrupt normal hematopoietic progenitor-cell growth at concentrations that inhibited activation-loop mutants of Kit. In a murine model, AP23848 inhibited activation-loop mutant Kit phosphorylation and tumor growth. Thus, AP23464 and AP23848 potently and selectively target activation-loop mutants of Kit in vitro and in vivo and could have therapeutic potential against D816V-expressing malignancies.

AB - Oncogenic mutations of the Kit receptor tyrosine kinase occur in several types of malignancy. Juxtamembrane domain mutations are common in gastrointestinal stromal tumors, whereas mutations in the kinase activation loop, most commonly D816V, are seen in systemic mastocytosis and acute myelogenous leukemia. Kit activation-loop mutants are insensitive to imatinib mesylate and have been largely resistant to targeted inhibition. We determined the sensitivities of both Kit mutant classes to the adenosine triphosphate (ATP)-based inhibitors AP23464 and AP23848. In cell lines expressing activation-loop mutants, low-nM concentrations of AP23464 inhibited phosphorylation of Kit and its downstream targets Akt and signal transducer and activator of transcription 3 (STAT3). This was associated with cell-cycle arrest and apoptosis. Wild-type Kit- and juxtamembrane-mutant-expressing cell lines required considerably higher concentrations for equivalent inhibition, suggesting a therapeutic window in which cells harboring D816V Kit could be eliminated without interfering with normal cellular function. Additionally, AP23464 did not disrupt normal hematopoietic progenitor-cell growth at concentrations that inhibited activation-loop mutants of Kit. In a murine model, AP23848 inhibited activation-loop mutant Kit phosphorylation and tumor growth. Thus, AP23464 and AP23848 potently and selectively target activation-loop mutants of Kit in vitro and in vivo and could have therapeutic potential against D816V-expressing malignancies.

UR - http://www.scopus.com/inward/record.url?scp=22044443112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044443112&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-12-4771

DO - 10.1182/blood-2004-12-4771

M3 - Article

C2 - 15746079

AN - SCOPUS:22044443112

VL - 106

SP - 227

EP - 234

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -